Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academics Conferences

Biography

Katrin Ramsauer (F), Head of preclinical and clinical development. Katrin Ramsauer graduated as PhD from the University of Vienna in the fields of Microbiology and Immunology. Since then she was working as a Post Doc at the Department of Virology in Vienna followed by a Post Doc in early Vaccines development at Novartis Vaccines in Cambridge, MA (USA). She joined Themis in 2010 to support the chikungunya vaccine project development at pre-clinical stage and was later leading the phase 1 clinical trial and regulatory interactions regarding ongoing and planned vaccine projects. Dr. Ramsauer is the author of several peer reviewed scientific papers and co-inventor on several patents.

Abstract

Themis’ is developing a safe, effective and affordable preventive vaccine platform against priority pathogen diseases that have the potential to cause epidemics such as Chikungunya or Zika virus infection by using a “plug-and play” vaccine technology. This technology is based on a measles vaccine vector (MV) that can be easily genetically modified to express immunoprotective proteins for designated emerging infectious pathogens. This delivery platform technology has already demonstrated proof of principle in humans through a Phase 1 clinical trial in 42 healthy volunteers with a recombinant measles vaccine against Chikungunya virus (MV-CHIK). We showed that the vaccine was well tolerated. One immunization induced functional, neutralizing antibodies in up to 90% of immunized subjects, a second immunization induced 100% seroconversion. Importantly, immunogenicity was independent of pre-existing anti-vector (measles) immunity. We show here a Phase 2 clinical trial to demonstrate the vaccine vector safety and immunogenicity in up to 300 subjects. Preliminary findings point at excellent safety and immunogenicity profile in the two doses tested. Data are currently under final evaluation and auditing, and will be presented here.

Special Issues
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by

Mail us at

Registration Query
vaccinesworld@alliedconferences.org
General Query
vaccinesworld@alliedmeetings.org
Abstract Submission
vaccinesworld@alliedconferences.org
More details about sponsorship:sponsors@alliedacademies.com
Copyright © 2017-2018 Allied Academies, All Rights Reserved.